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Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia
To the Editor: Cyclic neutropenia is a rare he-
matologic disease that is characterized by regu-
lar oscillations in blood neutrophil counts from 
normal levels (absolute neutrophil count [ANC], 
>1.5×109 per liter) to severe neutropenia (ANC, 
<0.2×109 per liter), usually with a cycle length of 
about 21 days.1 When patients with this disorder 
have neutropenia, they often have fever and mouth 
ulcers and are at risk for severe infections. Cyclic 
neutropenia is usually an autosomal dominant 
disorder caused by mutations in the gene encod-
ing neutrophil elastase (ELANE).2
We first reported the use of granulocyte colony-
stimulating factor (G-CSF) in patients with cyclic 
neutropenia 28 years ago.3 Shortly thereafter, a 
randomized clinical trial showed that G-CSF pre-
vented infections in such patients.4 Subsequently, 
we followed these patients and 350 others, in-
cluding 191 affected patients in 37 families, 
through the Severe Chronic Neutropenia Interna-
tional Registry (SCNIR), which records treatments, 
serious infections, hospitalizations, cancers, and 
deaths.5 We defined severe infection as hospital-
ization for infection requiring antibiotics (e.g., 
febrile neutropenia, pneumonia, bacteremia, and 
peritonitis).
The six patients in our original study are now 
between the ages of 38 and 94 years. Five of the 
six have ELANE mutations. The eldest, who does 
not have an ELANE mutation, had spontaneous 
improvement and stopped G-CSF. The other five 
patients have maintained good health while re-
ceiving G-CSF injections at least three times per 
week for nearly 30 years. One patient has de-
creased bone density, and idiopathic thrombocy-
topenic purpura developed in another; otherwise 
there have been no clinically significant compli-
cations. In aggregate, the six patients have re-
ceived more than 6.6 g of G-CSF over approxi-
mately 150 patient-years of observation.
Figure 1A summarizes data for 356 patients 
with cyclic neutropenia. Among the 239 patients 
who have been prospectively followed through 
the SCNIR (including the 6 patients from our 
original study), there was a consistent history of 
recurrent fevers, mouth ulcers, and infections 
before the initiation of G-CSF.3 In this group, 
there have been 18 episodes of severe infection 
(3 of which were fatal in patients who did not 
have substantial coexisting illness) among the 
patients who were not receiving G-CSF and 2 epi-
sodes among those who were receiving G-CSF 
(including 1 patient who also had chronic renal 
failure). Kaplan–Meier analysis suggests that 
G-CSF prevents severe infections in patients with 
cyclic neutropenia (P = 0.02) (Fig. 1B). An analy-
sis of the whole population of 356 patients, 
which included records from family histories, 
showed 36 episodes of sepsis in untreated pa-
tients, as compared with 2 in patients who were 
receiving G-CSF.
Adverse events have generally not limited G-CSF 
treatment of cyclic neutropenia. Bone pain, the 
most common adverse effect, usually abates with 
repeated injections. One patient who had never 
initiated treatment with G-CSF received a diag-
nosis of chronic myeloid leukemia that required 
hematopoietic stem-cell transplantation. One 
G-CSF–treated patient who was receiving long-
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term chronic immunosuppressive therapy for 
Henoch–Schönlein purpura underwent hemato-
poietic stem-cell transplantation for acute myeloid 
leukemia (AML). Another patient underwent 
transplantation as a primary treatment for cyclic 
neutropenia. None of these patients survived.
Since our original report, we have recorded 
nearly 3000 patient-years of treatment with G-CSF 
without other hematologic complications or cases 
of AML in treated patients and no AML in any 
known family members. On the basis of these 
long-term observations, we believe that G-CSF is 
a remarkably safe and effective treatment to 
prevent infections and improve the quality of life 
in patients with cyclic neutropenia.
David C. Dale, M.D. 
AudreyAnna Bolyard, R.N., B.S. 
Tracy Marrero,  
Vahagn Makaryan, M.D.
University of Washington 
Seattle, WA 
dcdale@uw.edu
Figure 1. Characteristics of the Patients and Efficacy of G-CSF in the Prevention of Sepsis.
Panel A summarizes data for 356 patients with cyclic neutropenia, including 239 patients who have been followed 
through the Severe Chronic Neutropenia International Registry (SCNIR). Shown are data regarding the presence  
or absence of mutations in the gene encoding neutrophil elastase (ELANE) and the efficacy of granulocyte colony-
stimulating factor (G-CSF) in preventing severe infections. Patients’ family members who also had neutropenia were 
considered to have cyclic neutropenia. Panel B shows Kaplan–Meier plots comparing the probability of freedom 
from sepsis among the patients who received G-CSF and those who did not. The inset shows the same data on an 
expanded y axis. The hash marks indicate censoring of data owing to a loss of follow-up, including deaths unrelated 
to sepsis events. The hazard ratio for freedom from sepsis was calculated by means of a Cox proportional-hazards 
model with G-CSF as a time-varying covariate.
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Tiotropium in Early-Stage COPD
To the Editor: Zhou and colleagues (Sept. 7 is-
sue)1 found that, in China, tiotropium was more 
effective than placebo in improving lung func-
tion and reducing the frequency of acute exacer-
bations of chronic obstructive pulmonary disease 
(COPD) among patients with disease of Global 
Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage 1 (mild) or 2 (moderate) severity. 
However, in China, patients with mild or moder-
ate COPD rarely present to health care providers 
with respiratory symptoms and, in our experi-
ence, seldom receive medications. Therefore, the 
key issues are whether there is a need to intro-
duce community-based screening to identify early-
stage disease and whether an intervention in this 
group with medication (as compared with target-
ed smoking-cessation advice, for example) would 
prove cost-effective. Do the authors recommend 
the introduction of widespread lung-function 
screening in China, and if so, how would they 
select the population for screening?
Guoqing Qian, M.D. 
Fengying Ying, M.D. 
Guoxiang Li, M.D.
Ningbo First Hospital 
Ningbo, China 
bill . qian@ outlook . com
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To the Editor: Declines in the forced expiratory 
volume in 1 second (FEV1) after bronchodilator 
use are thought to reflect long-term progressive 
deterioration in airway structures. However, Zhou 
et al. found no change at all between tiotropium 
and placebo over months 6 to 24 (Fig. 2A of the 
article, available at NEJM.org). The decline slopes 
were exactly parallel, with differences between 
the tiotropium group and the placebo group of 
109 ml at month 6 and 110 ml at month 24. The 
FEV1 in each group declined 60 ml over a period 
of 18 months of observation.
I do not think that there is some special benefit 
from tiotropium before month 6, because 29% 
of the patients in the placebo group (110 pa-
tients) and 16% of those in the tiotropium group 
(63 patients) withdrew before 6 months (Fig. 2C 
of the article). Missing data, not decline, is the 
likely explanation for the difference in the FEV1 
in the early months of the trial. A definitive 
long-term study has shown that tiotropium has 
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